|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boyero L, Sánchez-Gastaldo A, Alonso M,
Noguera-Uclés JF, Molina-Pinelo S and Bernabé-Caro R: Primary and
acquired resistance to immunotherapy in lung cancer: Unveiling the
mechanisms underlying of immune checkpoint blockade therapy.
Cancers (Basel). 12:37292020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilky BA: Immune checkpoint inhibitors:
The linchpins of modern immunotherapy. Immunol Rev. 290:6–23. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Patil NS, Nabet BY, Müller S, Koeppen H,
Zou W, Giltnane J, Au-Yeung A, Srivats S, Cheng JH, Takahashi C, et
al: Intratumoral plasma cells predict outcomes to PD-L1 blockade in
non-small cell lung cancer. Cancer Cell. 40:289–300.e4. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu
K: Combination strategies with PD-1/PD-L1 blockade: Current
advances and future directions. Mol Cancer. 21:282022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schoenfeld JD, Giobbie-Hurder A,
Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler
RD, Lee C, et al: Durvalumab plus tremelimumab alone or in
combination with low-dose or hypofractionated radiotherapy in
metastatic non-small-cell lung cancer refractory to previous
PD(L)-1 therapy: An open-label, multicentre, randomised, phase 2
trial. Lancet Oncol. 23:279–291. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao B, Zhao H and Zhao J: Efficacy of
PD-1/PD-L1 blockade monotherapy in clinical trials. Ther Adv Med
Oncol. 12:17588359209376122020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang H, Liu F, Chen X, Zhao C, Li X, Zhou
C, Hu J, Chu Q and Jiang T: Outcome differences between PD-1/PD-L1
inhibitors-based monotherapy and combination treatments in NSCLC
with brain metastases. Exp Hematol Oncol. 12:562023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bakke J and Haj FG: Protein-tyrosine
phosphatase 1B substrates and metabolic regulation. Semin Cell Dev
Biol. 37:58–65. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bai KH, Zhu MJ, Zhang YY, Li XP, Chen SL,
Wang DW and Dai YJ: Multi-omics analyses of tumor-associated
immune-infiltrating cells with the novel immune checkpoint protein
tyrosine phosphatase 1B (PTP1B) in extracellular matrix of
brain-lower-grade-glioma (LGG) and uveal-melanoma (UVM). Front
Immunol. 13:10538562022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wilson NS and Huntington ND: Small
molecule. Big biology. Dual phosphatase inhibitor enters the
immunotherapy fray. Immunol Cell Biol. 102:8–11. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wiede F, Lu KH, Du X, Zeissig MN, Xu R,
Goh PK, Xirouchaki CE, Hogarth SJ, Greatorex S, Sek K, et al: PTP1B
is an intracellular checkpoint that limits T-cell and CAR T-cell
antitumor immunity. Cancer Discov. 12:752–773. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zappasodi R, Merghoub T and Wolchok JD:
Emerging concepts for immune checkpoint blockade-based combination
therapies. Cancer Cell. 34:6902018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu L, Zhang X, Chen X, Yang D, Nie Y, Pan
R, Li L, Wang C, Gui H, Chen S, et al: Anti-TNFR2 enhanced the
antitumor activity of a new HMGN1/3M-052 stimulated dendritic cell
vaccine in a mouse model of colon cancer. Biochem Biophys Res
Commun. 653:106–114. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nie Y, Yang D, Trivett A, Han Z, Xin H,
Chen X and Oppenheim JJ: Development of a curative therapeutic
vaccine (TheraVac) for the treatment of large established tumors.
Sci Rep. 7:141862017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang X, Lao M, Xu J, Duan Y, Yang H, Li
M, Ying H, He L, Sun K, Guo C, et al: Combination cancer
immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces
immunosuppressive effects in the microenvironment of pancreatic
tumors. J Immunother Cancer. 10:e0039822022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bourebaba L, Serwotka-Suszczak A,
Bourebaba N, Zyzak M and Marycz K: The PTP1B inhibitor
trodusquemine (MSI-1436) improves glucose uptake in equine
metabolic syndrome affected liver through anti-inflammatory and
antifibrotic activity. Int J Inflam. 2023:38030562023.PubMed/NCBI
|
|
21
|
Jing Q, Wan Q, Nie Y, Luo J, Zhang X, Zhu
L, Gui H, Li L, Wang C, Chen S, et al: Ansofaxine hydrochloride
inhibits tumor growth and enhances Anti-TNFR2 in murine colon
cancer model. Front Pharmacol. 14:12860612023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang J, Dang F, Ren J and Wei W:
Biochemical Aspects of PD-L1 regulation in cancer immunotherapy.
Trends Biochem Sci. 43:1014–1032. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sharma B, Xie L, Yang F, Wang W, Zhou Q,
Xiang M, Zhou S, Lv W, Jia Y, Pokhrel L, et al: Recent advance on
PTP1B inhibitors and their biomedical applications. Eur J Med Chem.
199:1123762020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuan F, Gao Q, Tang H, Shi J and Zhou Y:
Ophiopogonin-B targets PTP1B to inhibit the malignant progression
of hepatocellular carcinoma by regulating the PI3K/AKT and AMPK
signaling pathways. Mol Med Rep. 25:1222022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bentires-Alj M and Neel BG:
Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced
breast cancer. Cancer Res. 67:2420–2424. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ocaranza P, Gaete X, Román R, Morales F,
Íñiguez G and Cassorla F: Phosphotyrosine phosphatases in
GH-stimulated skin fibroblasts from children with idiopathic short
stature. J Pediatr Endocrinol Metab. 26:833–840. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liang S, Tran E, Du X, Dong J, Sudholz H,
Chen H, Qu Z, Huntington ND, Babon JJ, Kershaw NJ, et al: A small
molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor
immunity. Nat Commun. 14:45242023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Penafuerte C, Feldhammer M, Mills JR,
Vinette V, Pike KA, Hall A, Migon E, Karsenty G, Pelletier J,
Zogopoulos G and Tremblay ML: Downregulation of PTP1B and TC-PTP
phosphatases potentiate dendritic cell-based immunotherapy through
IL-12/IFNγ signaling. Oncoimmunology. 6:e13211852017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu S, Lalani AI, Jin J, Sant'Angelo D,
Covey LR, Liu K, Young HA, Ostrand-Rosenberg S and Xie P: The
adaptor protein TRAF3 is an immune checkpoint that inhibits
myeloid-derived suppressor cell expansion. Front Immunol.
14:11679242023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ubil E, Caskey L, Holtzhausen A, Hunter D,
Story C and Earp HS: Tumor-secreted Pros1 inhibits macrophage M1
polarization to reduce antitumor immune response. J Clin Invest.
128:2356–2369. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lu S, Sun Z, Hu W, Yin S, Zhao C and Hu H:
PD-L1 positively regulates MET phosphorylation through inhibiting
PTP1B. Cancer Sci. 112:1878–1887. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao S, Gang J, Yu M, Xin G and Tan H:
Computational analysis for identification of early diagnostic
biomarkers and prognostic biomarkers of liver cancer based on GEO
and TCGA databases and studies on pathways and biological functions
affecting the survival time of liver cancer. BMC Cancer.
21:7912021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gao S, Tan H and Gang J: Inhibition of
hepatocellular carcinoma cell proliferation through regulation of
the Cell Cycle, AGE-RAGE, and Leptin signaling pathways by a
compound formulation comprised of andrographolide, wogonin, and
oroxylin A derived from Andrographis Paniculata(Burm.f.) Nees. J
Ethnopharmacol. 329:1180012024. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu R, Wang C, Li Z, Xiao J, Li C, Wang X,
Kong P, Cao J, Huang F, Li Z, et al: SOX2 promotes resistance of
melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity
that can be reversed by SAHA. J Immunother Cancer. 8:e0010372020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qu Y, Wang X, Bai S, Niu L, Zhao G, Yao Y,
Li B and Li H: The effects of TNF-α/TNFR2 in regulatory T cells on
the microenvironment and progression of gastric cancer. Int J
Cancer. 150:1373–1391. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gao S, Tan H and Li D: Oridonin suppresses
gastric cancer SGC-7901 cell proliferation by targeting the
TNF-alpha/androgen receptor/TGF-beta signalling pathway axis. J
Cell Mol Med. 27:2661–2674. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Medler J, Kucka K and Wajant H: Tumor
necrosis factor receptor 2 (TNFR2): An emerging target in cancer
therapy. Cancers (Basel). 14:26032022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Berdnikovs S, Pavlov VI, Abdala-Valencia
H, McCary CA, Klumpp DJ, Tremblay ML and Cook-Mills JM: PTP1B
deficiency exacerbates inflammation and accelerates leukocyte
trafficking in vivo. J Immunol. 188:874–884. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang J, Li L, Li J, Liu Y, Zhang CY,
Zhang Y and Zen K: Protein tyrosine phosphatase 1B impairs diabetic
wound healing through vascular endothelial growth factor receptor 2
dephosphorylation. Arterioscler Thromb Vasc Biol. 35:163–174. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mabeta P and Steenkamp V: The VEGF/VEGFR
axis revisited: Implications for cancer therapy. Int J Mol Sci.
23:155852022. View Article : Google Scholar : PubMed/NCBI
|
